GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuo Therapeutics Inc (OTCPK:AURX) » Definitions » Shiller PE Ratio

Nuo Therapeutics (Nuo Therapeutics) Shiller PE Ratio : (As of May. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nuo Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nuo Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Nuo Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuo Therapeutics Shiller PE Ratio Chart

Nuo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nuo Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nuo Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Nuo Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuo Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's Shiller PE Ratio falls into.



Nuo Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Nuo Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Nuo Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.02/129.4194*129.4194
=-0.020

Current CPI (Dec. 2023) = 129.4194.

Nuo Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -0.050 98.790 -0.066
201312 -0.050 98.326 -0.066
201403 -0.050 99.695 -0.065
201406 -0.090 100.560 -0.116
201409 -0.040 100.428 -0.052
201412 0.023 99.070 0.030
201503 0.020 99.621 0.026
201506 -0.010 100.684 -0.013
201509 -0.110 100.392 -0.142
201512 -0.340 99.792 -0.441
201603 -0.040 100.470 -0.052
201606 0.000 101.688 0.000
201609 -0.190 101.861 -0.241
201612 0.000 101.863 0.000
201703 -0.170 102.862 -0.214
201706 -0.390 103.349 -0.488
201709 -0.090 104.136 -0.112
201712 -0.352 104.011 -0.438
201803 -0.030 105.290 -0.037
201806 -0.030 106.317 -0.037
201809 -0.030 106.507 -0.036
201812 0.010 105.998 0.012
201903 -0.030 107.251 -0.036
201906 -0.020 108.070 -0.024
201909 -0.004 108.329 -0.005
201912 0.000 108.420 0.000
202009 -0.001 109.815 -0.001
202012 0.280 109.897 0.330
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 -0.029 117.630 -0.032
202203 -0.010 121.301 -0.011
202206 -0.020 125.017 -0.021
202209 -0.020 125.227 -0.021
202212 -0.020 125.222 -0.021
202303 -0.020 127.348 -0.020
202306 -0.020 128.729 -0.020
202309 -0.020 129.860 -0.020
202312 -0.020 129.419 -0.020

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nuo Therapeutics  (OTCPK:AURX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Nuo Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Nuo Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuo Therapeutics (Nuo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8285 El Rio, Suite 190, Houston, TX, USA, 77054
Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The Aurix product became commercially available for sale in current financial year.
Executives
Charles E Sheedy 10 percent owner TWO HOUSTON CENTER, SUITE 2907, HOUSTON TX 77010
David Emerson Jorden director, officer: CEO, CFO 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381
Lawrence Atinsky director 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
C Eric Winzer director
Paul Mintz director C/O NUO THERAPEUTICS INC., 207A PERRY PARKWAY, SUITE 1, GAITHERSBURG MD 20877
Peter Clausen officer: CSO 11204 JEFFRO COURT, IJAMSVILLE MD 21754
Scott M. Pittman director 3683 JOHN NASH BLVD., BLUEFIELD WV 24701
Boyalife Investment Fund I, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Dean Tozer officer: CHIEF COMMERCIAL OFFICER C/O ADVANCED BIOHEALING, INC., 36 CHURCH LANE, WESTPORT CT 06880
Steven A Shallcross officer: SEE REMARKS C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Aldagen Holdings, Llc 10 percent owner, other: May be part of a 13(d) group C/O THOMAS A. ALLEN, ESQ., 4101 LAKE BOONE TRAIL, STE 300, RALEIGH NC 27607
Kathryne Carr 10 percent owner, other: May be part of a 13(d) group 315 OLD IVY WAY, SUITE 101, CHARLOTTESVILLE VA 22903
William W Brooke 10 percent owner, other: May be part of a 13(d) group 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Guercio Joseph Del director C/O CLARK INVESTMENTS, 7500 OLD GEORGETOWN ROAD, SUITE 620, BETHESDA MD 20814
B. Jefferson Clark 10 percent owner, other: May be part of a 13(d) group C/O ALDAGEN, INC., 2810 MERDIAN PARKWAY, SUITE 148, DURHAM NC 27713